 Emmaus Life Sciences Inc OTCQX:EMMA reported its 3Q financial results that showed the company generated revenue of 5.8 million, up 3 from the 5.6 million it posted during the same period last year. The results showed the company is progressing its efforts to expand access to Endari, the firms prescription L-glutamine oral powder for the treatment of sickle cell disease. 